Influence of SLCO1B3 Polymorphisms on Pharmacodynamics of Mycophenolate Mofetil in Lupus Nephritis Patients
10.13748/j.cnki.issn1007-7693.20221573
- VernacularTitle:SLCO1B3基因多态性对狼疮性肾炎患者吗替麦考酚酯疗效的影响
- Author:
Xiaochun XIE
1
,
2
;
Qingling GU
3
;
Baijie XU
1
,
4
;
Shouqi MO
1
,
4
;
Xuzhen CAI
1
,
2
;
Lina HUANG
1
,
2
;
Min HUANG
3
;
Jiali LI
3
Author Information
1. Jieyang People&rsquo
2. s Hospital Department of Pharmacy
3. Institute of Clinical Pharmacology, School of Pharmacy, Sun Yat-sen University, Guangzhou 510080, China
4. s Hospital Division of Rheumatology, Jieyang 522000, China
- Publication Type:Journal Article
- Keywords:
mycophenolate mofetil；lupus nephritis； pharmacodynamics ； SLCO1B3； pharmacogenomics
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(1):133-137
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To investigate the effect of polymorphisms of solute carrier organic anion transporter family, member 1B3(SLCO1B3) gene on the pharmacodynamics of mycophenolate mofetil(MMF) in patients with lupus nephritis.
METHODS
Patients with lupus nephritis who were treated in Jieyang People’s Hospital from September 2019 to April 2021 were selected. All subjects were treated with MMF for at least 12 months, or discontinued due to poor efficacy. The efficacy of MMF was evaluated. The SLCO1B3 334T>G/699G>A(rs4149117/rs7311358) genotype was detected using Agena MassARRAY®, and the correlation between gene polymorphisms and MMF pharmacodynamics was analyzed using SPSS 25.0 software.
RESULTS
The genotype frequencies of SLCO1B3 334T>G/699G>A were in Hardy-Weinberg equilibrium. The probability of poor MMF treatment effect of 334GG/699AA carriers was significantly higher than that of 334TT/699AA and 334TG/699GA carriers(P<0.001); Logistic regression showed that both 334GG/699AA and urine protein>2.5 g·(24 h)−1 were the risk factors for poor MMF treatment[OR=4.038(1.731, 9.420), P<0.001; OR=4.157(1.705, 10.137), P=0.002]. Combined analysis showed that patients with both 334GG/699AA genotype and urine protein>2.5 g·(24 h)−1 were at higher risk for poor efficacy[OR=8.563(3.301, 22.216), P<0.001].
CONCLUSION
SLCO1B3 334T>G/699G>A is related to the efficacy of MMF treating lupus nephritis, and 334GG/699AA carriers are more likely to result in poor efficacy.
